BioNTech SE received approval from the European Medicines Agency (EMA) for the manufacture of the COVID-19 vaccine drug product at its facility in Marburg, one of BioNTech’s largest mRNA vaccine manufacturing sites in Europe with an annual production capacity of up to one billion doses of its COVID-19 vaccine, once fully operational.   Due to optimized operational efficiencies which were initiated last year, BioNTech has been able to increase the expected annual manufacturing capacity by 250 m...